A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability Assessment
Authors:
- 1 November 2023
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 41 (1) , 13-27
Abstract
Objective Manufacturing changes occur commonly throughout stages of biologics development and may result in product quality attribute changes. As changes in critical quality attributes have the potential to affect clinical safety and efficacy of products, it is imperative to ensure the quality and clinical performance before introducing the after-change products. Thus, we embarked on this project to understand what data have supported the manufacturing changes for licensed products with pre- and post-approval changes. Methods We surveyed the manufacturing changes of 85 monoclonal antibodies and 10 Fc fusion proteins approved by the Food and Drug Administration as of December 25, 2021. After collecting the type and timing of changes for these products, we investigated the approaches that provided supporting data for the changes. The source documents included reports submitted by applicants and FDA’s regulatory reviews. Results Analytical comparability was assessed to support all identified manufacturing changes. Supporting clinical data were available in 92% of these manufacturing changes; including data from pharmacokinetic comparability studies alone (3%), other studies on efficacy or safety (70%) and a combination of both (19%). Clinical pharmacokinetic comparability data contributed to supporting substantial changes, such as host cell type or master cell bank changes, concentration or formulation changes, and changes from pre-filled syringes to autoinjectors, especially when introduced after completing pivotal studies. Conclusion Our comprehensive retrospective analysis provides an understanding of the regulatory experience and industry practice, which could facilitate developing appropriate comparability approaches to support manufacturing changes in the future.Keywords
Funding Information
- Oak Ridge Institute for Science and Education
This publication has 36 references indexed in Scilit:
- Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodiesTrends in Biotechnology, 2010
- Use of a folding model and in situ spectroscopic techniques for rational formulation development and stability testing of monoclonal antibody therapeutics**Gauri Rao and Vandana Iyer contributed equally to this work.Journal of Pharmaceutical Sciences, 2010
- Effect of Production Method and Gene Amplification on the Glycosylation Pattern of a Secreted Reporter Protein in CHO CellsBiotechnology Progress, 2008
- Multifunctionality of Campylobacter jejuni sialyltransferase CstII: Characterization of GD3/GT3 oligosaccharide synthase, GD3 oligosaccharide sialidase, and trans-sialidase activitiesGlycobiology, 2008
- The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope: A carbohydrate of unique evolution and clinical relevanceBiochimica et Biophysica Acta (BBA) - General Subjects, 2008
- Process parameter shifting: Part II. Biphasic cultivation—A tool for enhancing the volumetric productivity of batch processes using Epo‐Fc expressing CHO cellsBiotechnology and Bioengineering, 2006
- The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cellsBiotechnology and Bioengineering, 2006
- Regulatory perspectives from Japan – Comparability of biopharmaceuticalsBiologicals, 2005
- Effects of buffering conditions and culture pH on production rates and glycosylation of clinical phase I anti‐melanoma mouse IgG3 monoclonal antibody R24Biotechnology and Bioengineering, 2003
- Improved Tumor Localization and Radioimaging with Chemically Modified Monoclonal AntibodiesCancer Biotherapy and Radiopharmaceuticals, 1996